Tranilast was recently suggested to exhibit antitumor activity against various types of cancers, including breast cancer, gastric cancer, and ESCC.[7,13] Regarding its effects on CSCs, we reported a novel mechanism by which tranilast suppresses CSCs that involves the inhibition of TRPV2.[7]. The gene discussed is TRPV2; the disease is esophageal squamous cell carcinoma.